New drug nafeprolol, a class 1.1 drug for asthma and COPD, was accepted by CDE
-
Last Update: 2015-04-22
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
At the same time that the imported COPD drugs are approved by the domestic clinic, the domestic new drug R & D enterprises are not willing to lag behind Naparo, a new 1.1 drug of Shandong Henley Pharmaceutical Technology Co., Ltd., was undertaken by CDE on April 16, 2015 and entered the evaluation center This is the second class 1.1 drug declared by Shandong Henry, and the other is amoquini (kbp-5074) for hypertension / diabetic nephropathy Among the seven new drugs on the research and development line of Shandong Henley medicine, kbp-5074, kbp-7072 and kbp-7026 are all in the stage of clinical application and clinical trial, and the website of Henley medicine shows that kbp-5074 and kbp-7026 have submitted clinical application in China Therefore, we have reason to guess that naparo is kbp-7026 Kbp-7026 is a selective chemokine receptor (CRTH2) inhibitor for the treatment of inflammatory and autoimmune diseases such as asthma and COPD Shandong Henley Pharmaceutical Co., Ltd., founded by Dr Huang Zhenhua, focuses on new drug innovation Other new drugs under development also involve bacterial infection, anti-tumor and other treatment fields.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
